MAINZ BIOMED N.V. Update: Nasdaq Listing Status

Here is the latest news regarding Mainz Biomed, explained simply so you can understand what is happening with your investment.

1. What happened?

Mainz Biomed (NASDAQ: MYNZ) received a formal warning from Nasdaq. The company failed to keep its share price above the $1.00 minimum required by exchange rules. The stock traded below this level for 30 business days in a row, triggering the notice.

2. When did it happen?

The company received this notification from Nasdaq on March 20, 2026.

3. Why did it happen?

Nasdaq requires a $1.00 minimum price to keep the market stable and maintain investor confidence. Mainz Biomed is a diagnostic company currently spending heavily to launch its main product, the ColoAlert® cancer screening test. Like many small biotech firms, the company faces pressure from high costs, expensive clinical trials, and a tough market for companies that aren't yet profitable.

4. Why does this matter?

There is no immediate impact on trading. You can still buy and sell "MYNZ" shares as usual. However, this notice acts as a "yellow flag." It shows the company’s market value has dropped. This may discourage large institutional investors and increases the risk of being moved to the "Over-the-Counter" market, where stocks are often harder to trade and more volatile.

5. Who is affected?

• Investors: Shareholders face more uncertainty. This notice often attracts short-sellers who bet the price will fall further or expect the company to issue more shares (which reduces your ownership percentage) or perform a reverse stock split.
• The Company: Management is now under strict watch. To fix this, the stock price must close at $1.00 or higher for at least ten business days in a row before the deadline.

6. What happens next?

Mainz Biomed has 180 days to fix this, ending on September 16, 2026. They have two main ways to regain compliance:

• Operational Milestones: The company can try to boost its stock price naturally by announcing successful trial results, new partnerships for ColoAlert®, or better sales figures.
• Reverse Stock Split: If the price stays low, the Board of Directors might combine existing shares into fewer, more expensive ones. This would mathematically push the price above $1.00, though it does not change the company's actual value.

7. What should investors know?

• Don't panic: This is a common regulatory step for growing biotech companies. It does not mean the company is going bankrupt or stopping operations.
• Watch the clock: September 16, 2026, is the key date. If they miss it, they might get another 180-day extension if they meet other financial requirements.
• Understand the risk: This warning can lead to more selling. Keep an eye on the company’s cash levels in their latest reports. You want to see if they have enough money to reach their goals without needing to issue more shares or perform a reverse split.

How to use this information

When deciding whether to hold or adjust your position, focus on the company's "burn rate"—how fast they are spending their cash—and any upcoming announcements regarding ColoAlert®. If you see positive news about commercial partnerships or clinical progress, that is the most likely way the company will regain compliance without resorting to a reverse split. If the company remains quiet, the risk of a reverse split or further price volatility increases.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and should not be considered financial advice. Always do your own research before making investment decisions.